Clinical trials: Secondary Coronary Prevention
Secondary Coronary Prevention
The NOR-COR Study for Coronary Prevention
The NOR-COR study is a cross-sectional, observational study designed to explore a large number of cardiovascular, inflammatory, genetic, behavioral, and psychosocial factors (including anxiety, depression, quality of life) in…
- Trial name
- NCT02309255
- Testing
- no intervention
- Where
- Norway
- Volunteers
- 975 people, healthy volunteers welcome
- Sponsor
- Vestre Viken Hospital Trust
Cardiac Transplantation, Skin Cancer
CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial
Heart transplant is a recognized therapeutic strategy in refractory heart failure. Its success is however hampered by severe cancer occurrence and recurrence.
- Trial name
- CERTICOEUR (NCT00799188)
- Testing
- Everolimus
- Where
- France
- Volunteers
- 175 people
- Sponsor
- Hospices Civils de Lyon
Coronary Disease
Self-management and Theory-based Rehabilitation Encouraging New Gateways to Healthy-Hearts
The goal of this intervention is translate current behaviour change in to community cardiac rehabilitation programmes for people living beyond a heart attack.
- Trial name
- STRENGTH (NCT05705310)
- Testing
- Self Management Strategies
- Where
- United Kingdom
- Volunteers
- 96 people
- Sponsor
- University of Ulster
Acute Coronary Syndromes, Chronic Coronary Syndromes
EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention
Cluster Randomized Trial to test the effectiveness of a patient level delivered educational intervention to improve the awareness on the relevance of obtaining LDL cholesterol recommended goals in patients admitted for an acute…
- Trial name
- EARLY (NCT07252388)
- Testing
- Patient-oriented educational intervention
- Where
- 30 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Heart Care Foundation
Acute Coronary Syndrome
Secondary Prevention in Acute Coronary Syndromes: A CALIBER Study
All contemporary guidelines for secondary prevention in acute coronary syndromes recommend a combination of aspirin, beta-blockers, ACE-inhibitors and statins. Yet underutilisation of these drugs is common.
- Trial name
- NCT01162187
- Volunteers
- 400,000 people
- Sponsor
- University College, London
Post Coronary Artery Bypass Grafting, Hypertension
"Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients
This study aims to evaluate the effect of an AI-assisted "Smart family doctor" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-CABG (coronary artery bypass…
- Conditions
- Post Coronary Artery Bypass Grafting, Hypertension, Diabetes Mellitus, Hyperlipidemia
- Trial name
- SMART (NCT06615609)
- Testing
- Smart family doctor, Health manager
- Where
- China
- Volunteers
- 536 people
- Sponsor
- China National Center for Cardiovascular Diseases
Socioeconomic Status, Secondary Prevention
Socioeconomic Status, Secondary Prevention Activities and Recurrence After a Myocardial Infarction
This is a nationwide cohort study on real-world patients (n≈30,000) surviving a first myocardial infarction (MI) 2006-2013 and alive to attend a routine 1-year follow-up.
- Conditions
- Socioeconomic Status, Secondary Prevention, Myocardial Infarction, Cardiovascular Disease
- Trial name
- NCT04199663
- Volunteers
- 30,191 people
- Sponsor
- Karolinska Institutet
Coronary Heart Disease
Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: an RCT
The substitution of polyunsaturated fatty acids (PUFA) for saturated fatty acids (SFA) is a cornerstone of worldwide dietary advice for coronary heart disease (CHD) risk reduction.
- Trial name
- NCT01621087
- Testing
- Safflower oil
- Where
- Australia
- Volunteers
- 458 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Myocardial Infarction, Stroke
Psychosocial Risk Factors in Stroke and Myocardial Infarction
The aim of this study is to identify groups of subjects at risk of recurrence in secondary prevention based on Psychosocial Factors.
- Trial name
- INEV@L (NCT02824107)
- Testing
- blood sample, questionnaires for psychosocial factors
- Where
- France
- Volunteers
- 294 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Atrial Fibrillation
High-intensity Interval Training in Patients With Atrial Fibrillation
A key characteristic of the heart is its regular rhythm. When the heart is exposed to irregular electric impulses, such as with atrial fibrillation (AF), detrimental effects can occur affecting the ability of the heart to pump…
- Trial name
- HIIT-AF (NCT05354271)
- Testing
- High-intensity interval training, Moderate-intensity continuous training
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- Liverpool John Moores University
Cardiac Rehabilitation
Cardiac Rehabilitation and Ongoing Physical Activity During COVID-19
The current Coronavirus Disease 2019 (COVID-19) pandemic has resulted in extraordinary public health orders of social distancing and self-isolation, leading to widespread disruption and discontinuation of cardiac rehabilitation…
- Trial name
- CODIS (NCT04501432)
- Testing
- No intervention
- Where
- Austria
- Volunteers
- 27 people
- Sponsor
- Ludwig Boltzmann Institute for Digital Health and Prevention
Angina, Unstable, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
Rehabilitation After Acute Coronary Syndrome: a New Telemonitoring Strategy
Cardiac rehabilitation after an acute coronary syndrome is recognised in the latest guidelines and recommendations published by the major scientific societies as a class I indication.
- Conditions
- Angina, Unstable, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT04942977
- Testing
- telemonitoring, Centre-based cardiac rehabilitation
- Where
- 2 sites in Spain
- Volunteers
- 67 people
- Sponsor
- Catcronic Salut SL
Heart Failure, Frailty
FAiling HearT in the Elderly (FATE) Study
In 2015 the Italian Ministry of Health invited the Cardiac Research Hospitals of Italy to constitute a Cardiac Network. The aim of the network is to facilitate and promote scientific and technological research in the setting of…
- Trial name
- FATE (NCT06343233)
- Testing
- usual care
- Where
- 7 sites in Italy
- Volunteers
- 5,000 people
- Sponsor
- IRCCS Multimedica
Atrial Fibrillation, Stroke
WATCHMAN for Second Prevention of Stroke (WASPS)
To evaluate the effects of mechanical left atrial appendage (LAA) closure for secondary prevention of stroke in the patients with nonvalvular atrial fibrillation
- Trial name
- NCT03327350
- Testing
- WATCHMAN transplantation, Oral anticoagulant drugs
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Defibrillators, Tachycardia
Observational Study of Patient Comprehension, Perception, Fears and Appreciation Following Home-Monitoring Implementation
Describe the mutual influences between trainings realized in implantation centers, medico-technical knowledges, technical implementation, perception, fears and appreciation felt by the patients during Home Monitoring…
- Trial name
- Educ@t (NCT01006746)
- Testing
- Remote monitoring by Home Monitoring system
- Where
- France
- Volunteers
- 571 people
- Sponsor
- Biotronik France
Coronary Heart Disease
Feasability of Collaborative Care in the Secondary Prevention of Coronary Heart Disease
The main focus of the pilot study is to evaluate the feasability and effectiveness of a collaborative care intervention for patients suffering from a coronary heart disease (CHD) with insufficient controlled health related risk…
- Trial name
- NCT02389153
- Testing
- collaborative care CHD
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Göttingen
Rheumatic Heart Disease, Rheumatic Heart Disease in Children
Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease
The overall objective is to evaluate the effectiveness of a school-centered primary and secondary prevention program on the prevalence of latent rheumatic heart disease among schoolchildren in Nepal, and to investigate the role…
- Trial name
- NEPAL4 (NCT05504928)
- Testing
- School nurse program
- Where
- Nepal
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Rheumatic Fever, Valvular Heart Diseases
Improving Management and Secondary Prevention Through Azithromycin Comparative Trial in Rheumatic Heart Disease in Nigeria)- IMPACT-RHD Nigeria
Background: Nigeria, among other Low and Middle-income countries, bears one of the highest burdens of RHD in Africa, affecting young to middle-aged adults within their productive years.
- Conditions
- Rheumatic Fever, Valvular Heart Diseases, Valvular Cardiomyopathy
- Trial name
- IMPACT-RHD (NCT07625228)
- Testing
- Benzathine Penicillin, Azithromycin (Azithro)
- Volunteers
- 474 people
- Sponsor
- Ladoke Akintola University of Technology, Ogbomoso, Nigeria
Coronary Heart Disease, Artificial Intelligence
Effects of AI Assisted Follow-up Strategy on Secondary Prevention in CABG Patients
The present study is trying to find out whether artificial intelligence assisted follow-up strategy will improve secondary prevention in CABG patients.
- Conditions
- Coronary Heart Disease, Artificial Intelligence, Sleep Apnea
- Trial name
- NCT04636996
- Testing
- artificial intelligence assisted follow-up
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC